Device: titanium cage (DrugBank: Titanium)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 70 | Spinal stenosis | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03532945 (ClinicalTrials.gov) | October 28, 2010 | 2/5/2018 | A Follow-up Study to Evaluate the Efficacy and Safety of Novomax in Posterior Lumbar Interbody Fusion | A Long-term Follow-up Study to Evaluate the Efficacy and Safety for the Patients With Bioactive Glass-ceramic Intervertebral Spacer (Novomax) in Posterior Lumbar Interbody Fusion: Comparison With a Titanium Cage | Degenerative Lumbar Spinal Stenosis | Device: Bioactive Glass-Ceramic Spacer;Device: Titanium cage | BioAlpha Inc. | NULL | Completed | 30 Years | 80 Years | All | 62 | N/A | NULL |